Paolo Giuffrida

🇮🇹

[Paolo Giuffrida @GiuffridaPaolo]

Great energy in Palermo for this first day of @AISP_Pancreas meeting for the management of #pancreatic cystic lesions. #guidelines, pitfalls, mistakes and way to improve our daily clinical practice
Thanks to #AISP for such a great work

[Roberto Cannella @cannella_rob]

Prima giornata del corso @AISP_Pancreas lesioni cistiche e solide del pancreas a Palermo

@PBoraschi @Blondie_GZ @DrF_Vernuccio @lelecapurso @GiuffridaPaolo

[Jahnvi Dhar @DharJahnvi]

Happy to share our latest publication online in @endoscopyjrnl 😇

"Bleeding giant pseudoaneurysm non-visualized on arterial phase imaging: Endoscopic ultrasound-guided angioembolization to the rescue" 🥰

@Jayanta_sam

@Dr_AntrikshKr @PankajG55222170

[Anand Sahai @AnandSahaiEUS]

Good RCTs of EUS-BD vs ERCP finally coming out. https://t.co/sWhNf39Snq

[Paolo Giuffrida @GiuffridaPaolo]

Amazing hands on training at #ESGEDays2023 on #endoscopic hemostasis. Thanks to @xerobal for being such a great trainer and for all the tips and tricks
@ESGE_news @Graceffa1992

[Paolo Giuffrida @GiuffridaPaolo]

At #ENDOBOAT2023, Prof. Fusaroli shows how to perform #EUS guided tissue acquisition of pancreatic lesion.
Thanks to the Vivascope technology, #anatomopathologists make immediate diagnosis of #PDAC
#Forli #endoscopy #EUS

[Nino Cartabellotta @Cartabellotta]

Stiamo andando verso una #sanità "a doppio binario” con l’aggravante che le Regioni del Sud rischiano di diventare clienti di quelle del Nord
#SalviamoSSN

https://t.co/xBlCf1Gc5J

[Federica Vernuccio @DrF_Vernuccio]

The word Alliance will improve patient care & cure!
This joint conference #gastroenterology + #endoscopy + #radiology organized by @AISP_Pancreas on #PancreaticCancer is the way to go
Honored to be Faculty with @PBoraschi @cannella_rob @Blondie_GZ @TV_Bartolotta @GiuffridaPaolo

[Paolo Giuffrida @GiuffridaPaolo]

Good luck to the new @AisfFegato Secretary
Congratulations Prof.@Calvar1Vincenza
#promiseUNIPA @unipa_it

[Paolo Giuffrida @GiuffridaPaolo]

Innovative data presented by an outstanding @CiroCelsa at #AISF2023
@AisfFegato
@PROMISEUnipaHCC

[Giuseppe Cabibbo @cabibbo78]

It was a pleasure to comment with Julien Edeline, on the study by Talbot et al Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma.
https://t.co/Gm5E0OlpbQ
https://t.co/gsCjQxlz2r

[Paolo Giuffrida @GiuffridaPaolo]

https://t.co/JWvPHhG78g

[Paolo Giuffrida @GiuffridaPaolo]

Glad to be presenting a clincal case of #PancreaticCancer and to witness an amazing Prof. Marco Giovannini performing #EUS guided #hepaticogastrostomy at #endoboat #pentaxmedical

[Giuseppe Cabibbo @cabibbo78]

BCLC 2022 update. Discussing outcomes in advanced HCC with @bruixj @ma5RN @LorenzaRimassa Jordi Rimola and Roman Kloeckner

[Roberto Cannella @cannella_rob]

I'm happy to share our new review discussing the evolving scenario in the assessment of radiological
response for hepatocellular carcinoma in the era of
#Immunotherapy!

@GiuffridaPaolo @CiroCelsa @cabibbo78 @PROMISEUnipaHCC

Find out more: https://t.co/fBI51Q7XoY

[PROMISE-UNIPA-HCC Group @PROMISEUnipaHCC]

#HCC Sicily network. The Sicilian #Gastroenterology school in Rome

[Paolo Giuffrida @GiuffridaPaolo]

Former italian health minister @BeaLorenzin pointing the importance of using #DAAs against #HCV to prevent #hepatocellularcarcinoma
The Italian experience
@PROMISEUnipaHCC @cabibbo78 @CiroCelsa #LiverCancerAwarenessMonth

[Paolo Giuffrida @GiuffridaPaolo]

Inspiring faculty at the 2nd @AisfFegato training day in #Rome
Prof Cammà showing the complexity behind #surrogates #endpoint in #HCC
Prof. De Franchis and Prof. @Calvar1Vincenza pointing out the history of #Baveno and what’s new in @BavenoVII
@PROMISEUnipaHCC, #unipa

[Ciro Celsa @CiroCelsa]

https://t.co/XgBkzIveMh The field of systemic treatments for #HCC is expanding, as well as controversies on RCTs interpretation. We discuss surrogate endpoints, downstream therapies and patient selection on @TheLancetOncol w/@cabibbo78 @DJPinato @A_DAlessioMD @FulgenziClaudia

[Arndt Vogel @ArndtVogel]

🔥Is response associated with OS in #HCC❓

👉Our post-hoc analysis of REFELCT
@JHepatology
https://t.co/xiub7jQvN5

✅mOS twice as long in responders vs non-responders
👇PR vs SD vs PD
🔥Lenvatinib valid option in 1st line ->LEAP-02

@EASLedu #LiverTwitter @myESMO @OncoAlert